Characteristics of 57 cases of PML after rituximab treatment
| Characteristic . | All patients (n = 57) . | Transplanted patients* (n = 8) . | Nontransplanted patients (n = 49) . |
|---|---|---|---|
| Median age, y (range) | 61 (30-89) | 47.5 (30-60) | 63 (44-89) |
| Male, % | 43.8 | 62.5 | 41.7 |
| Indication for rituximab treatment | |||
| Chronic lymphocytic leukemia, % | 24.6 | 0 | 24.5 |
| Follicular lymphoma, % | 19.3 | 12.5 | 20.4 |
| Diffuse large B-cell lymphoma, % | 12.3 | 25.0 | 10.4 |
| Non-Hodgkin lymphoma, % | 17.5 | 25.0 | 16.3 |
| Waldenstrom macroglobulinemia, % | 5.3 | 0 | 6.3 |
| Mantle cell lymphoma, % | 3.5 | 12.5 | 2.0 |
| Marginal zone B-cell lymphoma, % | 3.5 | 12.5 | 2.0 |
| Small lymphocytic lymphoma, % | 3.5 | 0 | 4.1 |
| Burkitt lymphoma, % | 1.8 | 0 | 2.0 |
| Autoimmune hemolytic anemia, % | 3.5 | 12.5 | 2.0 |
| Systemic lupus erythematosus, % | 3.5 | 0 | 4.1 |
| Rheumatoid arthritis, % | 1.8 | 0 | 2.0 |
| Immune thrombocytopenic purpura, % | 1.8 | 0 | 2.0 |
| Autoimmune pancytopenia, % | 1.8 | 0 | 2.0 |
| Previous chemotherapy exposure | |||
| Corticosteroid, % | 78.9 | 87.5 | 75.5 |
| Cyclophosphamide, % | 73.7 | 87.5 | 69.4 |
| Vinca alkaloid, % | 57.9 | 75.0 | 53.1 |
| Purine nucleoside analog, % | 45.6 | 12.5 | 51.0 |
| Anthracycline, % | 49.1 | 62.5 | 44.9 |
| Chlorambucil, % | 21.1 | 75.0 | 24.5 |
| Etoposide, % | 19.3 | 62.5 | 12.2 |
| Platinum compound, % | 17.5 | 62.5 | 10.2 |
| Cytarabine, % | 21.0 | 25.0 | 12.2 |
| Alemtuzumab, % | 1.8 | 0 | 2.0 |
| Presenting symptoms | |||
| Confusion, mental status changes, % | 54.4 | 37.5 | 57.1 |
| Focal motor weakness, hemiparesis, % | 33.3 | 37.5 | 30.6 |
| Loss of motor coordination, % | 24.6 | 25.0 | 24.5 |
| Speech changes, % | 21.1 | 37.5 | 18.4 |
| Vision changes, % | 17.5 | 12.5 | 18.4 |
| Method of PML diagnosis | |||
| MRI findings and JCV DNA in CSF, % | 54.4 | 50.0 | 55.1 |
| Brain biopsy, % | 35.1 | 50.0 | 32.7 |
| Autopsy, % | 8.8 | 0 | 10.2 |
| Survival† | 10.4 | 25.0 | 6.5 |
| Median rituximab doses (before diagnosis), (range) | 6 (1-28) | 4 (2-16) | 6 (1-28) |
| Median first dose to PML diagnosis, mo (range) | 16.0 (1.0-90.0) | 24.0 (1.0-90.0) | 14.0 (1.8-66.9) |
| Median last dose to PML diagnosis, mo (range) | 5.5 (0.3-66.0) | 6.0 (0.3-22.9) | 5.5 (0.4-66.0) |
| PML diagnosis to death, mo (range) | 2.0 (0.4-12.2) | 2.0 (1.0-7.1) | 2.5 (0.4-12.2) |
| Median previous and concomitant chemotherapy treatments (range) | 4 (1-14) | 8 (3-10) | 4 (1-14) |
| Characteristic . | All patients (n = 57) . | Transplanted patients* (n = 8) . | Nontransplanted patients (n = 49) . |
|---|---|---|---|
| Median age, y (range) | 61 (30-89) | 47.5 (30-60) | 63 (44-89) |
| Male, % | 43.8 | 62.5 | 41.7 |
| Indication for rituximab treatment | |||
| Chronic lymphocytic leukemia, % | 24.6 | 0 | 24.5 |
| Follicular lymphoma, % | 19.3 | 12.5 | 20.4 |
| Diffuse large B-cell lymphoma, % | 12.3 | 25.0 | 10.4 |
| Non-Hodgkin lymphoma, % | 17.5 | 25.0 | 16.3 |
| Waldenstrom macroglobulinemia, % | 5.3 | 0 | 6.3 |
| Mantle cell lymphoma, % | 3.5 | 12.5 | 2.0 |
| Marginal zone B-cell lymphoma, % | 3.5 | 12.5 | 2.0 |
| Small lymphocytic lymphoma, % | 3.5 | 0 | 4.1 |
| Burkitt lymphoma, % | 1.8 | 0 | 2.0 |
| Autoimmune hemolytic anemia, % | 3.5 | 12.5 | 2.0 |
| Systemic lupus erythematosus, % | 3.5 | 0 | 4.1 |
| Rheumatoid arthritis, % | 1.8 | 0 | 2.0 |
| Immune thrombocytopenic purpura, % | 1.8 | 0 | 2.0 |
| Autoimmune pancytopenia, % | 1.8 | 0 | 2.0 |
| Previous chemotherapy exposure | |||
| Corticosteroid, % | 78.9 | 87.5 | 75.5 |
| Cyclophosphamide, % | 73.7 | 87.5 | 69.4 |
| Vinca alkaloid, % | 57.9 | 75.0 | 53.1 |
| Purine nucleoside analog, % | 45.6 | 12.5 | 51.0 |
| Anthracycline, % | 49.1 | 62.5 | 44.9 |
| Chlorambucil, % | 21.1 | 75.0 | 24.5 |
| Etoposide, % | 19.3 | 62.5 | 12.2 |
| Platinum compound, % | 17.5 | 62.5 | 10.2 |
| Cytarabine, % | 21.0 | 25.0 | 12.2 |
| Alemtuzumab, % | 1.8 | 0 | 2.0 |
| Presenting symptoms | |||
| Confusion, mental status changes, % | 54.4 | 37.5 | 57.1 |
| Focal motor weakness, hemiparesis, % | 33.3 | 37.5 | 30.6 |
| Loss of motor coordination, % | 24.6 | 25.0 | 24.5 |
| Speech changes, % | 21.1 | 37.5 | 18.4 |
| Vision changes, % | 17.5 | 12.5 | 18.4 |
| Method of PML diagnosis | |||
| MRI findings and JCV DNA in CSF, % | 54.4 | 50.0 | 55.1 |
| Brain biopsy, % | 35.1 | 50.0 | 32.7 |
| Autopsy, % | 8.8 | 0 | 10.2 |
| Survival† | 10.4 | 25.0 | 6.5 |
| Median rituximab doses (before diagnosis), (range) | 6 (1-28) | 4 (2-16) | 6 (1-28) |
| Median first dose to PML diagnosis, mo (range) | 16.0 (1.0-90.0) | 24.0 (1.0-90.0) | 14.0 (1.8-66.9) |
| Median last dose to PML diagnosis, mo (range) | 5.5 (0.3-66.0) | 6.0 (0.3-22.9) | 5.5 (0.4-66.0) |
| PML diagnosis to death, mo (range) | 2.0 (0.4-12.2) | 2.0 (1.0-7.1) | 2.5 (0.4-12.2) |
| Median previous and concomitant chemotherapy treatments (range) | 4 (1-14) | 8 (3-10) | 4 (1-14) |